Acumen Pharmaceuticals Inc - Asset Resilience Ratio
Acumen Pharmaceuticals Inc (ABOS) has an Asset Resilience Ratio of 57.32% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Acumen Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Check ABOS capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Acumen Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Acumen Pharmaceuticals Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $76.60 Million | 57.32% |
| Total Liquid Assets | $76.60 Million | 57.32% |
Asset Resilience Insights
- Very High Liquidity: Acumen Pharmaceuticals Inc maintains exceptional liquid asset reserves at 57.32% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Acumen Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Acumen Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Acumen Pharmaceuticals Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Acumen Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 51.19% | $62.88 Million | $122.83 Million | -5.69pp |
| 2024-12-31 | 56.88% | $135.93 Million | $238.99 Million | -0.08pp |
| 2023-12-31 | 56.96% | $176.64 Million | $310.12 Million | +32.79pp |
| 2022-12-31 | 24.16% | $47.50 Million | $196.59 Million | -7.13pp |
| 2021-12-31 | 31.29% | $72.08 Million | $230.33 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $44.43 Million | -- |
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement… Read more